

Award Number: W81XWH-11-1-0815

TITLE: Pathophysiology of Post Amputation Pain

PRINCIPAL INVESTIGATOR: Dr. R. Norman Harden

CONTRACTING ORGANIZATION: Rehabilitation Institute of Chicago  
Chicago, IL 60611

REPORT DATE: December 2014

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE December 2014		2. REPORT TYPE FINAL		3. DATES COVERED 26SEP2011 – 25SEP2014	
4. TITLE AND SUBTITLE Pathophysiology of Post Amputation Pain				5a. CONTRACT NUMBER  W81XWH-11-1-0815	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. R. Norman Harden  EMAIL: nharden@ric.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Rehabilitation Institute of Chicago Chicago, IL 60611				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Post amputation pain (PAP) is highly prevalent and a prominent factor in disability, yet we know little about the specific pathophysiology. The number of amputees in the United States is over 450,000 with an estimated 1,300 from Operations Iraqi and Enduring Freedom. Studies indicate an incidence of PAP ranging between 64- 100% and prevalence over 80%. Conversely, only 1% of veterans with PAP reported lasting benefit from any treatment attempted. It is very likely that this failure to identify effective treatments stems from the lack of a coherent or comprehensive theory of pathophysiology; thus the rationale for this proposal. Based on our preliminary data we hypothesized that there is distinct and measurable pathophysiology(s) of the peripheral, central and sympathetic nervous systems that occur in response to the amputation of a limb. New technologies and novel implementation of standard techniques allowed us to clarify these explicit mechanisms. The study was designed using validated psychometric, psychophysical and biometric testing correlated with standard (afferent) regional nerve/neuroma and (efferent) sympathetic nerve blocks, in the final results, we will report descriptive statistics and pain reports, and report on brain anatomical reorganization with phantom limb pain.					
15. SUBJECT TERMS- NOTHING LISTED					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	28	19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
<b>1. Introduction.....</b>	<b>4</b>
<b>2. Keywords.....</b>	<b>4</b>
<b>3. Accomplishments.....</b>	<b>4</b>
<b>4. Impact.....</b>	<b>5</b>
<b>5. Changes/Problems.....</b>	<b>5</b>
<b>6. Products.....</b>	<b>6</b>
<b>7. Participants &amp; Other Collaborating Organizations.....</b>	<b>13</b>
<b>8. Special Reporting Requirements.....</b>	<b>14</b>
<b>9. Appendices.....</b>	<b>15</b>

---

1. **INTRODUCTION:** Post amputation pain (PAP) is highly prevalent and a prominent factor in disability, yet we know little about the specific pathophysiology. The number of amputees in the United States is over 450,000 with an estimated 1,300 from Operations Iraqi and Enduring Freedom. Studies indicate an incidence of PAP ranging between 64-100% and prevalence over 80%. Conversely, only 1% of veterans with PAP reported lasting benefit from any treatment attempted. It is very likely that this failure to identify effective treatments stems from the lack of a coherent or comprehensive theory of pathophysiology; thus the rationale for this proposal. Based on our preliminary data we hypothesized that there is distinct and measurable pathophysiology(s) of the peripheral, central and sympathetic nervous systems that occur in response to the amputation of a limb. New technologies and novel implementation of standard techniques allowed us to clarify these explicit mechanisms. The study was designed using validated psychometric, psychophysical and biometric testing correlated with standard (afferent) regional nerve/neuroma and (efferent) sympathetic nerve blocks, in the final results, we will report descriptive statistics and pain reports, and report on brain anatomical reorganization with phantom limb pain.
2. **KEYWORDS:** Post amputation pain, pathophysiology, peripheral nervous system, afferent nervous system, central nervous system, sympathetic nervous system
3. **ACCOMPLISHMENTS:**
  - **What were the major goals of the project?**
    - **Year one:** Regulatory documents completed recruitment schemes developed and implemented
    - Database developed
    - Logistics of experiment and scheduling
    - All devices synched standardized as to process and field tested
    - Pilot subject enrolled and analyzed
    - Begin experimentation
    - **Year two:**
      - The main body of experimentation
      - Data analysis
      - Report, abstracting ,and publication of results
  - **What was accomplished under these goals?**
    - Major activities included:
      - Final recruitment for the experiment
      - Training of residents and staff for final push of recruitment
      - Scheduling of experiment for subjects
      - Ordering of new supplies for injections
      - Recruitment analysis
      - Implementation for final recruitment push
      - Planning meetings for data analysis
      - Analysis meeting and plan for data of fMRI
      - Analysis meeting for the rest of the data

- Data base cleaning and calculating of all total scores
  - Final report and analysis
- **What opportunities for training and professional development has the project provided**  
 This project has provided methodology to perform studies in the future with post amputation pain. Using the fMRI was a unique component and there are no studies currently that have looked at post amputation in the same way. The study coordinators are now better equipped to recruit for this population having plans in place that pinpoint the targeted subject population and are effective. The coordination of the study was between several different teams at different locations, the study was able to be executed between all of these teams in a timely manner and can provide methodology for future consortium studies that are similar.
- **How were the results disseminated to communities of interest?**  
 Results will be presented at American Pain Society, American Academy of Pain Medicine, Midwest Pain Society, American Academy of Physical Medicine and Rehabilitation. The results will be published in *Pain*, *Pain Medicine* and *Journal of Pain* as well as specialty journals interested in specifics of methodology (e.g. fMRI)
- **What do you plan to do during the next reporting period to accomplish the goals?**  
 This is the final report; we are analyzing data and preparing for dissemination, as above.
- **What was the impact on the development of the principal discipline(s) of the project?**  
 This project developed the methodology of brain scans in the post amputation pain population and the use of ultrasound guided neuroma injection. We also explored the impact of sympathetically maintained pain in PAP, methods for defining that and safety of sympathetic blocks in this population. Systems, consortium research, and statistical methods we created and preliminarily validated.
- **What was the impact on other disciplines?**  
 Teams from different backgrounds and institutions came together to collaborate and fulfill a common goal. Many other members of the scientific team were trained and volunteered their time. This experiment has provided the knowledge that collaboration was one of the most important factors in providing a successful outcome. Professionals from Physical Medicine and Rehabilitation, Neurology, Anesthesiology and Brain Imaging worked together, and will publish results in their respective areas.
- **What was the impact on technology transfer?** New methods of ultrasound and brain imaging technology were developed
- 4. **What was the impact on society beyond science and technology**  
 This study provided insight into an underserved population where treatments are needed and very little is known. Developing concepts of mechanisms of disease is pre-imminent to developing effective therapy. The brain imaging that was completed will provide

information about the brain in a unique population, perhaps assisting in the conceptualization of human pain in general.

5. **CHANGES/PROBLEMS:** Nothing to report.
6. **PRODUCTS:** Nothing to report

### **Other Products:**

Results from the basic aims of the experiment will be discussed in this report. Psychometric, psychophysical and biometric data will be assessed and correlated in this underserved diagnosis. These results will establish a framework for near term publications and academic debate as well as methodology for future experiments.

### **Methods:**

Four groups randomly generated determined the treatment injection that the subject received during the second visit: 1) sympathetic nerve block of bupivacaine located in either the neck or lower back (depending on where the participant's amputation is located), or 2) dry needling located in either the neck or lower back (depending on where the participant's amputation is located), or 3) neuroma injection of bupivacaine or 4) dry needling at the neuroma. Baseline psychometric measures included: McGill Pain Questionnaire - Short Form (MPQ), Center for Epidemiological Studies Depression Scale (CES-D 10), Pain and Anxiety Symptoms Scale, short version (PASS-20), and the Pain Disability Index (PDI). Independent samples t-tests were used to analyze the short term efficacy of the medication in terms of change in Visual Analogue Scale (VAS) and Numeric Rating Scale (NRS) pain scores before and 15 minutes, and 1 hour after the injection. Long term efficacy was analyzed by independent samples t-test comparing McGill Pain Questionnaire – Short Form (MPQ), VAS, Pain Anxiety Symptoms Scale (PASS), [Center for Epidemiological Studies Depression Scale](#) (CESD10) and Pain Disability Index (PDI) scores at visit 2 and visit 3 (2 weeks post injection). The MPQ was filled out with two forms to differentiate between phantom limb pain (PL) and residual limb pain (RL).

### **Demographics and Pain Levels**

Subjects were selected according to the inclusion/exclusion criteria and basic demographic information was collected. The minimum age is 28 years old and maximum is 82 years old, with a mean of 53.38 years old (Table 1). Pain levels were measured using the numeric rating scale (NRS). Subjects would be asked on their pain level now, on a scale of 0-10, with 0 being no pain at all, and 10 being the worst pain imaginable. Subjects were asked to differentiate between phantom limb pain and residual limb pain. NRS is used to establish a baseline for comparison after intervention. The averages for the first visit are 3.87 for residual limb pain and 3.60 for phantom limb pain (Table 1). The maximum pain level for residual limb was an 8/10, and phantom limb pain was 7/10, with the minimum for both residual and phantom being 0/10 (Table 1). The reason that pain may have been a zero and subject were still included is because the pain they had was episodic or able to be reproduced by stimulating parts of their amputated limb.

Other demographics collected included race, ethnicity and sex. Of the 16 patients, 56% were African/African American, 37% were Caucasian/Russo-European, and 6% classified themselves as other (Table 2). There were more males in the study than females (Table 2). There was only one patient of Hispanic/Latino descent in this study.

	N	Minimum	Maximum	Mean	Std. Deviation
Age	16	28	82	53.38	13.817
NRS residual limb V1	15	0	8	3.87	2.446
NRS phantom limb V1	15	0	7	3.60	2.501

**Table 1: Age and Pain Levels**

	Total	Percent
African American	9	57%
Caucasian/Russo-European	6	37%
Other	1	6%
Total	16	100%

**Table 2: Race**

	Total	Percent
Females	5	32%
Males	11	68%

**Table 3: Sex**

### **Psychometrics and Pain Levels:**

A total of 16 participants were enrolled in the study. Of those, 9 received a neuroma injection and 5 received a sympathetic block. 9 subjects received an injection of bupivacaine, while 5 received sham (placebo) injections. No differences between treatment and control conditions reached statistical significance, but participants receiving treatment evidenced better outcomes in several measures.

All subjects who received a sympathetic block showed a decrease in NRS scores. The placebo group showed a non-significant decrease in average phantom limb pain NRS compared to drug (-2.0 and -.33 respectively  $p=.404$ ) at 15 minutes post injection. However, the injection/drug group showed a non-significant decrease in phantom limb pain at 1 hour post injection compared to placebo (-3.5 vs -1.0, respectively  $p=.155$ ). For residual limb pain, drug group showed a larger decrease in NRS compared to placebo at both 15 minutes (-1.67 and -1.0, respectively  $p=.658$ ) and 1 hour post injection (-2.0 and -.5, respectively  $p=.543$ ). (See table 4)

In the neuroma injection group, phantom limb pain decreased in the drug group, while pain increased in the placebo group at 15 minutes post injection (-1.0 and 1.33  $p=.151$ ). At 1 hour post injection, subjects in the drug group reported lower phantom limb pain, while pain was unchanged in the placebo group (-.33 and 0.0,  $p=.495$ ). Residual limb pain decreased in the drug group, while pain increased in the placebo group at 15 minutes post injection (-2.2 and .667  $p=.221$ ). However, both group showed a non-significant increase in pain after 1 hour (.33 and 3.0  $p=.366$ ). (see table 4)

Participants in the treatment group generally experienced greater improvements in self reported psychometric measures from V2-V3 when compared to controls, although no statistically significant differences were observed between groups. The drug group reported greater reductions on the PDI (-8.4 and -0.80,  $p=.510$ ), CES-D (-2.0 and 0.40  $p=.482$ ), MPQ-PL (-0.9 and -0.09,  $p=.442$ ), VAS-RL (-5.5 and 3.3  $p=.635$ ), and VAS-PL (-5.9 and -1.3  $p=.687$ ) compared to the placebo group. The placebo group reported greater reductions in only one outcome, the PASS (-7.8 and -1.5,  $p=.626$ ). Both drug and placebo groups reported non significant decreases in MPQ-RL (-0.87 and -0.83  $p=.961$ ). (see table 5)



Table 4: Change in Pain after Sympathetic block.

			mean	SD	p-value
VAS-Residual Limb Pain	placebo	2	-12.25	6.71751	0.161
	drug	3	8	13.85641	
VAS-Phantom Limb Pain	placebo	2	-7.5	4.94975	0.317
	drug	3	20	30.61046	
NRS-Phantom Limb Pain (15 minutes post)	placebo	2	-2	0	0.404
	drug	3	-0.3333	2.3094	
NRS-Phantom Limb Pain (1 hour post)	placebo	2	-1	1.41421	0.155
	drug	3	-3.5	0.70711	
NRS-Residual Limb Pain (15 minutes post)	placebo	2	-1	1.41421	0.658
	drug	3	-1.6667	1.52753	
NRS-Residual Limb Pain (1 hour post)	placebo	2	-0.5	0.70711	0.543
	drug	3	-2	2.82843	

Table 5: Change in Pain after Neuroma Injection.

			mean	SD	p-value
VAS-Residual Limb Pain	placebo	3	-4.8333	34.79344	0.812
	drug	5	-10.1	25.7449	
VAS-Phantom Limb Pain	placebo	3	12.6667	17.03917	0.164
	drug	5	0.14	5.51797	
NRS-Phantom Limb Pain (15 minutes post)	placebo	3	1.3333	0.57735	0.151
	drug	5	-1	2.34521	
NRS-Phantom Limb Pain (1 hour post)	placebo	3	0	0	0.495
	drug	5	-0.3333	0.57735	
NRS-Residual Limb Pain (15 minutes post)	placebo	3	0.6667	0.57735	0.141
	drug	5	-2.2	3.49285	
NRS-Residual Limb Pain (1 hour post)	placebo	3	3	4.24264	0.533
	drug	5	0.3333	1.52753	


	<b>Control (n=5)</b>	<b>Treatment (n=9)</b>	<b>p- value</b>
<b>PDI</b>	-0.8	-8.4	0.51
<b>PASS</b>	-7.8	-1.5	0.626
<b>CES-D</b>	0.4	-2	0.482
<b>MPQ RL</b>	-0.83	-0.87	0.961
<b>MPQ PL</b>	-0.09	-0.9	0.442
<b>VAS RL</b>	3.3	-5.5	0.635
<b>VAS PL</b>	-1.3	-5.9	0.687

**Table 6: Control and treatment groups with self reported outcomes**

### **Brain anatomical reorganization with phantom limb pain:**


Brain anatomy was examined in 9 patients with right or left leg amputations, with the time since amputation ranging from 1.6 to 18.3 years (Mean  $\pm$  SD: 9.6 $\pm$ 6.5 years). All patients reported phantom limb symptoms, including phantom limb pain. Given that phantom limb sensations reflect aberrant sensory processes in the central nervous system, and may be accompanied by altered motor function related either to the affected limb or other intact limbs, we turned our attention to the ample brain imaging evidence that has identified distinct sensory and motor regions mediating the subjective representation and motor control of the lower limbs. Specifically, we hypothesize that the brain communication patterns and anatomy that characterize these sensory and motor regions of the brain are fundamentally altered by abnormal sensory input and motor output at the residual limb. The identification of these key regions in brain anatomy will thus allow us to evaluate altered brain function that correlates with clinically relevant symptoms that can be assessed by physicians.

To investigate the gray matter (neuronal) brain characteristics of these patients, we used magnetic resonance brain imaging to obtain T1-weighted anatomical images. Given that gray matter is known to atrophy with increasing age, we identified T1 images from sex- and age-matched healthy individuals to serve as the control group (control age range: 28-78, Mean  $\pm$  SD: 53.2 $\pm$ 15.6; patient age range: 28-82, Mean  $\pm$  SD: 54.8 $\pm$ 17.2; 7 males, 2 females in each group). Group differences in gray matter density were evaluated using the voxel based morphometry toolkit provided by the FMRIB Software Library (FSL).



**Figure 1** – (A) Gray matter density in the caudate nucleus is greater in amputees ( $n = 8$ , age:  $54.8 \pm 17.2$  s.d.) than in sex and age matched controls ( $n = 8$ , age:  $53.2 \pm 15.6$  s.d.) ipsilateral to the site of amputation. Three individuals with left side amputation had their brains reflected along the left-right axis to align amputation related abnormalities across subjects, and the same procedure was applied to their paired controls. The statistically significant region of peak differences is shown (permutation test  $t > 2.3$ , cluster  $p < 0.05$ ) (B) Post-hoc examination of the gray matter density of the cluster in (A) illustrates the robust difference between amputees and controls. Median (black line), mean (red line) and interquartile range of gray matter density are shown, corrected for age and brain volume. There were no outliers. Gray matter density is represented as the volume fraction constituted by gray matter rather than white matter or cerebral spinal fluid.

Findings revealed increased gray matter density in the ipsilateral caudate nucleus in patients compared to healthy controls, and this increased density may reflect growth of dendrites, neuronal hypertrophy, local recruitment of glial cells, and/or changes in vasculature. The caudate nucleus is involved in involuntary and voluntary directed movement that facilitates accurate movements and body posture; for example, caudate anatomy is altered in patients with Parkinson's disease who progressively lose voluntary motor control. However, the presence of increased gray matter density ipsilateral (rather than contralateral) to the side of amputation suggests these changes may not directly relate to the phantom sensations. Rather, this observation may represent other brain processes that lead to and are reinforced by compensatory motor behavior of the residual limb. Therefore, in an effort identify brain anatomical changes more directly associated with the amputated limb, we performed a second statistical analysis targeting primary motor and somatosensory cortices contralateral to amputation, as well as areas within these regions that correlated with duration since amputation (i.e., regions that reflect the chronic impact of amputation including phantom sensations).



**Figure 2** Patients ( $n = 8$ ) show areas in primary somatosensory and motor cortices that correlate (red) and anticorrelate (blue) with duration since amputation. (A) Four prominent clusters are visible in the hemisphere contralateral to amputation which show positive or negative correlations with duration since amputation in lower limb amputees (voxel-wise  $t > 2.3$ , no cluster correction). The two most prominent of these are in regions of the somatosensory cortex in the vicinity of the somatotopic mapping of upper or lower limb regions (yellow and blue circles, resp). Additionally a region of the motor cortex in the vicinity of foot region is highlighted (green circle) because we have strong *a priori* reasons to expect reorganization in this region. (B) Post-hoc examination of gray matter in these three regions of interest illustrates an especially robust correlation with duration in the lateral S1 region. Controls are shown as a reference, but regression lines represent the relationship among patients alone, since this most accurately reflects the analysis in (A). Data corrected for age and brain volume.

To determine the clinical relevance of these anatomical alterations, we performed planned post-hoc analyses that revealed a correlation between pain intensity and gray matter density of medial M1 (the putative foot motor region) and the caudate (table I). The relationship between clinical pain intensity and altered brain anatomy provides strong support that our findings are clinically meaningful to this patient population.

	Variable	t	p-value
Caudate GM	<i>Age</i>	9.85	0.001
	<i>brain volume</i>	0.13	0.904
	Phantom Pain	2.76	0.051
	NRS		
Medial M1 GM	<i>Age</i>	-6.26	0.008
	<i>brain volume</i>	-5.31	0.013
	<i>Duration</i>	2.93	0.061
	Phantom Pain	-3.20	0.049
	(NRS)		

**Table I** Correlation between phantom pain intensity and previously identified regions of interest. Ipsilateral caudate shows a borderline correlation with phantom pain intensity (after controlling for confounding covariates). Medial M1 also shows a significant correlation with phantom pain after controlling for confounding covariates (age and brain volume) and the prior covariate of interest (duration; if we don't control for phantom pain, duration has  $p = 0.03$ , consistent with results in figure 2).

## 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

- What individuals have worked on the project?

### *Example:*

Elias	Study Team
Abousaad	Member
A. Vania	Co-
Apkarian	Investigator
Sally Cocjin	Study Team
	Member
Kelly	Study Team
Comstock	Member
Sara	Study Team
Connolly	Member
Melissa	Study Team
Farmer	Member
Joseph	Study Team
Graciosa	Member
R. Norman	PI

Harden	
Andrew Hendrix	Study Team Member
Kristina Herrmann	Study Team Member
Lejian Huang	Study Team Member
Danny Issa	Study Team Member
Katherine Khazey	Study Team Member
Amy Kirsling	Study Team Member
Maxine Kuroda	Study Team Member
Taif Mukhdomi	Study Team Member
Monica Rho	Study Team Member
Meryem Saracoglu	Study Team Member
Natalie Simak	Study Team Member
Steven Stanos	Study Team Member
Peng Yu	Study Team Member

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

No

**What other organizations were involved as partners?**

Northwestern University

- 8. SPECIAL REPORTING REQUIREMENTS:** No collaborative awards were used, and Quad charts were not used in this trial

## 9. APPENDICES:

### Bibliography and References Cited from protocol

1. Jensen TS, Krebs B, Nielsen J, Rasmussen P. Phantom limb, phantom pain and stump pain in amputees during the first 6 months following limb amputation. *Pain* 1983;17:243-56.
2. Pitres A. Etude sur les sensations illusoires des amputés. *Ann Med Psychol* 1897;5:177-92.
3. Jensen TS, Rasmussen P. Amputation. In: Wall PD, Melzack R, Bonica JJ, eds. *Textbook of pain*. Edinburgh; New York: Churchill Livingstone; 1984.
4. Abramson AS, Feibel A. The phantom phenomenon: its use and disuse. *Bull N Y Acad Med* 1981;57:99-112.
5. Carlen PL, Wall PD, Nadvorna H, Steinbach T. Phantom limbs and related phenomena in recent traumatic amputations. *Neurology* 1978;28:211-7.
6. Harden RN, Gagnon CM, Gallizzi M, Khan AS, Newman D. Residual limbs of amputees are significantly cooler than contralateral intact limbs. *Pain Pract* 2008;8:342-7.
7. Harden RN, Gagnon CM, Khan A, Wallach G, Zereszki A. Hypoesthesia in the Distal Residual Limb of Amputees. *PM R* 2010;2:607-11.
8. Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. *Pain* 1984;18:83-95.
9. Davis RW. Phantom sensation, phantom pain, and stump pain. *Arch Phys Med Rehabil* 1993;74:79-91.
10. Keil G. [So-called initial description of phantom pain by Ambroise Pare. "Chose digne d'admiration et quasi incredible": the "douleur es parties mortes et amputees"]. *Fortschr Med* 1990;108:62-6.
11. Mitchell SW. *Injuries of the nerves and their consequences*. Philadelphia: J.B. Lippincott & Co; 1872.
12. Whyte AS, Niven CA. Variation in phantom limb pain: results of a diary study. *J Pain Symptom Manage* 2001;22:947-53.
13. Kooijman CM, Dijkstra PU, Geertzen JH, Elzinga A, van der Schans CP. Phantom pain and phantom sensations in upper limb amputees: an epidemiological study. *Pain* 2000;87:33-41.
14. Wall PD, Gutnick M. Ongoing activity in peripheral nerves: the physiology and pharmacology of impulses originating from a neuroma. *Exp Neurol* 1974;43:580-93.
15. Wall P, Devor M. Physiology of sensation after peripheral nerve injury, regeneration and neuroma formation. In: Waxman S, ed. *Physiology and Pathobiology of Axons*. New York: Raven Press; 1978.
16. Wall PD, Waxman S, Basbaum AI. Ongoing activity in peripheral nerve: injury discharge. *Exp Neurol* 1974;45:576-89.
17. Cajal SR. *Degeneration and Regeneration in the Nervous System*. New York: Hafner; 1959.
18. Noordenbos W. Pain problems pertaining to the transmission of nerve impulses which give rise to pain. Elsevier, Amsterdam; 1959.
19. Devor M, Claman D. Mapping and plasticity of acid phosphatase afferents in the rat dorsal horn. *Brain Res* 1980;190:17-28.

20. Harden RN. Cytokine imbalance/activity as a unifying hypothesis for the pathogenesis and pathophysiology of Complex Regional Pain Syndrome? *Pain* 2011;152:247-8.
21. Uceyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. *Pain* 2007;132:195-205.
22. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. *Pain* 1992;48:261-8.
23. Hogan QH, Abram SE. Neural blockade for diagnosis and prognosis. A review. *Anesthesiology* 1997;86:216-41.
24. Melzack R. Phantom limb pain: Implications for treatment of pathologic pain. *Anesthesiology* 1971;35:409-16.
25. Dostrovsky JO, Millar J, Wall PD. The immediate shift of afferent drive to dorsal column nucleus cells following deafferentation: a comparison of acute and chronic deafferentation in gracile nucleus and spinal cord. *Exp Neurol* 1976;52:480-95.
26. Devor M, Wall PD. Reorganisation of spinal cord sensory map after peripheral nerve injury. *Nature* 1978;276:75-6.
27. Hunt SP, Mantyh PW. The molecular dynamics of pain control. *Nat Rev Neurosci* 2001;2:83-91.
28. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. *Nature* 1983;306:686-8.
29. Sugimoto T, Bennett GJ, Kajander KC. Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: effects of a chronic constriction injury, transection, and strychnine. *Pain* 1990;42:205-13.
30. Hanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. *J Pain Symptom Manage* 2000;20:50-8.
31. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. *Neurobiol Dis* 1998;5:209-27.
32. Peyron R, Garcia-Larrea L, Gregoire MC, et al. Parietal and cingulate processes in central pain. A combined positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) study of an unusual case. *Pain* 2000;84:77-87.
33. Witting N, Kupers RC, Svensson P, Arendt-Nielsen L, Gjedde A, Jensen TS. Experimental brush-evoked allodynia activates posterior parietal cortex. *Neurology* 2001;57:1817-24.
34. Iadarola MJ, Berman KF, Zeffiro TA, et al. Neural activation during acute capsaicin-evoked pain and allodynia assessed with PET. *Brain* 1998;121 ( Pt 5):931-47.
35. Petrovic P, Ingvar M, Stone-Elander S, Petersson KM, Hansson P. A PET activation study of dynamic mechanical allodynia in patients with mononeuropathy. *Pain* 1999;83:459-70.
36. Peyron R, Garcia-Larrea L, Gregoire MC, et al. Allodynia after lateral-medullary (Wallenberg) infarct. A PET study. *Brain* 1998;121 ( Pt 2):345-56.
37. Borsook D, Becerra L, Fishman S, et al. Acute plasticity in the human somatosensory cortex following amputation. *Neuroreport* 1998;9:1013-7.
38. Karl A, Birbaumer N, Lutzenberger W, Cohen LG, Flor H. Reorganization of motor and somatosensory cortex in upper extremity amputees with phantom limb pain. *J Neurosci* 2001;21:3609-18.
39. Sica RE, Sanz OP, Cohen LG, Freyre JD, Panizza M. Changes in the N1-P1 component of the somatosensory cortical evoked response in patients with partial limb amputation. *Electromyogr Clin Neurophysiol* 1984;24:415-27.



40. Roricht S, Meyer BU, Niehaus L, Brandt SA. Long-term reorganization of motor cortex outputs after arm amputation. *Neurology* 1999;53:106-11.
41. Apkarian A, Baliki M, Sosa Y, et al. Nonlinear analysis of ratings of spontaneous fluctuations of pain in chronic back pain may have diagnostic value. *J Pain* 2003;4:19.
42. Apkarian A, Baliki M, Sosa Y, et al. Chronic back pain perception is mediated through orbitofrontal activity: An fMRI study of spontaneous fluctuations on ongoing pain. *J Pain* 2003;4:19.
43. Casey KL. Forebrain mechanisms of nociception and pain: analysis through imaging. *Proc Natl Acad Sci U S A* 1999;96:7668-74.
44. Casey KL, Minoshima S, Morrow TJ, Koeppe RA. Comparison of human cerebral activation pattern during cutaneous warmth, heat pain, and deep cold pain. *J Neurophysiol* 1996;76:571-81.
45. Tracey I, Becerra L, Chang I, et al. Noxious hot and cold stimulation produce common patterns of brain activation in humans: a functional magnetic resonance imaging study. *Neurosci Lett* 2000;288:159-62.
46. Bridges D, Thompson SW, Rice AS. Mechanisms of neuropathic pain. *Br J Anaesth* 2001;87:12-26.
47. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. *Science* 2000;288:1765-9.
48. Byers MR, Bonica JJ. Peripheral pain mechanisms and nociceptor plasticity. In: Loeser JD, ed. *Bonica's Management of Pain*. Philadelphia: Lippincott Williams & Wilkins; 2001.
49. Melzack R, Bromage PR. Experimental phantom limbs. *Exp Neurol* 1973;39:261-9.
50. Birbaumer N, Lutzenberger W, Montoya P, et al. Effects of regional anesthesia on phantom limb pain are mirrored in changes in cortical reorganization. *J Neurosci* 1997;17:5503-8.
51. Davis KD, Kiss ZH, Luo L, Tasker RR, Lozano AM, Dostrovsky JO. Phantom sensations generated by thalamic microstimulation. *Nature* 1998;391:385-7.
52. Flor H, Elbert T, Muhlneckel W, Pantev C, Wienbruch C, Taub E. Cortical reorganization and phantom phenomena in congenital and traumatic upper-extremity amputees. *Exp Brain Res* 1998;119:205-12.
53. Melzack R, Israel R, Lacroix R, Schultz G. Phantom limbs in people with congenital limb deficiency or amputation in early childhood. *Brain* 1997;120:1603-20.
54. Willoch F, Rosen G, Tolle TR, et al. Phantom limb pain in the human brain: unraveling neural circuitries of phantom limb sensations using positron emission tomography. *Ann Neurol* 2000;48:842-9.
55. Lotze M, Flor H, Grodd W, Larbig W, Birbaumer N. Phantom movements and pain. An fMRI study in upper limb amputees. *Brain* 2001;124:2268-77.
56. Katz J. Psychophysiological contributions to phantom limbs. *Can J Psychiatry* 1992;37:282-98.
57. Sherman R, Sherman C, Bruno G. Psychological factors influencing chronic phantom pain: An analysis of the literature. *Pain* 1978;28:285-95.
58. Shukla GD, Sahu SC, Tripathi RP, Gupta DK. A psychiatric study of amputees. *Br J Psychiatry* 1982;141:50-3.
59. Parkes CM. Factors determining the persistence of phantom pain in the amputee. *J Psychosom Res* 1973;17:97-108.

60. Pawela CP, Biswal BB, Hudetz AG, et al. Interhemispheric neuroplasticity following limb deafferentation detected by resting-state functional connectivity magnetic resonance imaging (fcMRI) and functional magnetic resonance imaging (fMRI). *NeuroImage* 2010;49:2467-78.
61. Draganski B, Moser T, Lummel N, et al. Decrease of thalamic gray matter following limb amputation. *NeuroImage* 2006;31:951-7.
62. Harden R, Newman D, Daschbach P, et al. Is post amputation pain sympathetically maintained? *The Journal of Pain* 2005;6:S24-S.
63. Katz J. Psychophysical correlates of phantom limb experience. *J Neurol Neurosurg Psychiatry* 1992;55:811-21.
64. Campbell J, Raja S, Meyer R. Painful sequelae of nerve injury. In: Dubner R, Gebhart G, Bond M, eds. *Proceedings of the Fifth World Congress on Pain*. Amsterdam: Elsevier; 1988:135-43.
65. Roberts WJ. A hypothesis on the physiological basis for causalgia and related pains. *Pain* 1986;24:297-311.
66. Livingston WK. Phantom limb pain. A report of ten cases in which it was treated by injections of procaine hydrochloride near the thoracic sympathetic ganglions. *Archives of Surgery* 1938;37:353-70.
67. Kallio K. Permanency of results obtained by sympathetic surgery in the treatment of phantom pain. *Acta Orthop Scand* 1950;19:391-7.
68. Harden RN, Bruhl SP. Complex Regional Pain Syndrome. In: Fishman SM, Ballantyne JC, Rathmell JP, eds. *Bonica's Management of Pain*. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2010:314-31.
69. Harden RN, Rudin NJ, Bruhl S, et al. Increased systemic catecholamines in complex regional pain syndrome and relationship to psychological factors: a pilot study. *Anesth Analg* 2004;99:1478-85.
70. Raja SN, Treede RD, Davis KD, Campbell JN. Systemic alpha-adrenergic blockade with phentolamine: a diagnostic test for sympathetically maintained pain. *Anesthesiology* 1991;74:691-8.
71. Torebjork E, Wahren L, Wallin G, Hallin R, Koltzenburg M. Noradrenaline-evoked pain in neuralgia. *Pain* 1995;63:11-20.
72. Baron R, Maier C. Reflex sympathetic dystrophy: skin blood flow, sympathetic vasoconstrictor reflexes and pain before and after surgical sympathectomy. *Pain* 1996;67:317-26.
73. Livingston WK. *Pain Mechanisms*. New York: MacMillan; 1943.
74. Blumberg H, Janig W. Changes of reflexes in vasoconstrictor neurons supplying the cat hindlimb following chronic nerve lesions: a model for studying mechanisms of reflex sympathetic dystrophy? *J Auton Nerv Syst* 1983;7:399-411.
75. Jänig W. Causalgia and reflex sympathetic dystrophy: In which way is the sympathetic nervous system involved? *Trends in Neurosciences* 1985;8:471-7.
76. Janig W, Koltzenburg M. What is the interaction between the sympathetic terminal and the primary afferent fiber? In: Basbaum AI, Besson JM, eds. *Towards a New Pharmacotherapy of Pain*. Chichester: John Wiley & Sons; 1991:331-52.
77. Janig W, Koltzenburg M. Possible ways of sympathetic afferent interaction. In: Janig W, Schmidt RF, eds. *Reflex Sympathetic Dystrophy: Pathophysiological Mechanisms and Clinical Implications*. New York: VCH Verlagsgesellschaft; 1992:213-43.

78. Devor M. Nerve pathophysiology and mechanisms of pain in causalgia. *J Auton Nerv Syst* 1983;7:371-84.
79. Sliosberg A. *Les algies des amputes*. Paris: Masson; 1948.
80. Kristen H, Lukeschitsch G, Plattner F, Sigmund R, Resch P. Thermography as a means for quantitative assessment of stump and phantom pains. *Prosthet Orthot Int* 1984;8:76-81.
81. Sherman R. Direct evidence of a link between burning phantom pain and stump blood circulation: A case report. *Orthopedics* 1984;7:1319-20.
82. Sherman RA, Bruno GM. Concurrent variation of burning phantom limb and stump pain with near surface blood flow in the stump. *Orthopedics* 1987;10:1395-402.
83. Nystrom B, Hagbarth KE. Microelectrode recordings from transected nerves in amputees with phantom limb pain. *Neurosci Lett* 1981;27:211-6.
84. Daschbach P, Houle T, Newman D, Ranjbaran Z, Hyun P, Harden R. Is etiology of amputation correlated with psychophysiological and psychosocial aspects of pain? *The Journal of Pain* 2005;6:S24-S.
85. Arnold G, Wille O, Harden R, Gagnon C. (683): Concordance between different subsets of the post-amputation population is the rule: An analysis of psychophysical variables. *The Journal of Pain* 2007;8:S21-S.
86. Harden RN, Khan AS, Gagnon C, Daschbach P, DiMaio A, Kuiken T. PR\_148: The Assessment of Quantitative Sensory Testing in Postamputation Patients. *Archives of Physical Medicine and Rehabilitation* 2006;87:e29-e.
87. Harden RN, Kahn A, Zinke J, DiMaio A, Gagnon C. Distal residual limbs in amputees show significant cold perception hypoesthesia. *J Pain* 2006;7:S62.
88. Harden RN, Bruehl S, Stanos S, et al. Prospective examination of pain-related and psychological predictors of CRPS-like phenomena following total knee arthroplasty: a preliminary study. *Pain* 2003;106:393-400.
89. Harden RN, Houle TT, Green S, et al. Biofeedback in the treatment of phantom limb pain: a time-series analysis. *Appl Psychophysiol Biofeedback* 2005;30:83-93.
90. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. *Lancet* 1999;353:1959-64.
91. Swank S, Weber N, Fleming N, Harden RN. Sympathetic Autonomic Exacerbation of Phantom Limb Pain: A Pilot Study. *Journal of the American Osteopathic Association* 2010;110:448.
92. Weber N, Harden RN, Gagnon CM. Is post amputee pain a sympathetically maintained pain? Poster presented at: The Midwest Pain Society Chicago, IL; October 2007.
93. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. *Pain* 2011;152:S49-64.
94. Rolke R, Magerl W, Campbell KA, et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. *Eur J Pain* 2006;10:77-88.
95. Dotson RM. Clinical neurophysiology laboratory tests to assess the nociceptive system in humans. *J Clin Neurophysiol* 1997;14:32-45.
96. Yarnitsky D. Quantitative sensory testing. *Muscle Nerve* 1997;20:198-204.
97. Gruener G, Dyck PJ. Quantitative sensory testing: methodology, applications, and future directions. *J Clin Neurophysiol* 1994;11:568-83.
98. Harden R N, Khan AS, Gagnon CM, et al. The assessment of quantitative sensory testing in post-amputation patients. Poster presented: The American Academy of Physical Medicine and Rehabilitation 67th Annual Assembly and Technical Exhibition Honolulu, HI; November 2006.

99. Shy ME, Frohman EM, So YT, et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2003;60:898-904.
100. Harden R, Khan A, Zinke J, DiMaio A, Gagnon C. Distal residual limbs in amputees show significant cold perception hypoesthesia. In: Poster presented at the American Pain Society Annual Conference, San Antonio, TX; 2006.
101. Khan A, Zinke J, Daschbach P, Ranjbaran Z, Kuiken T, Harden RN. Post amputation residual limbs are cooler than contralateral unaffected limbs. Poster presented: The Midwest Pain Society Annual Meeting Chicago, IL; September 9-10, 2005.
102. Khan AS, Harden RN, Gagnon C, et al. An evaluation of post-amputation limbs using infrared telethermography, temperature strips and physical examination. Poster presented at: The 67th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation Honolulu, HI; November 2006.
103. Richeh W, Harden R. Mechanical hyperesthesia and cold perception hypoesthesia in distal residual limbs of amputees. *The Journal of Pain* 2010;11:S13-S.
104. Daschbach P, Ranjbaran Z, Hyun P, et al. Hypoesthesia in post amputation residual limbs. Presented at: The Midwest Pain Society Annual Meeting Chicago, IL; September 9-10, 2005.
105. Apkarian AV, Grachev ID, Krauss BR, Szeverenyi NM. Methods in imaging human brain pathophysiology of chronic pain. In: Kruger L, ed. *Methods in Pain Research*. Boca Raton: CRC Press; 2002:241-62.
106. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. *Eur J Pain* 2005;9:463-84.
107. Davis KD, Taylor KS, Hutchison WD, et al. Human anterior cingulate cortex neurons encode cognitive and emotional demands. *J Neurosci* 2005;25:8402-6.
108. Apkarian AV, Thomas PS, Krauss BR, Szeverenyi NM. Prefrontal cortical hyperactivity in patients with sympathetically mediated chronic pain. *Neurosci Lett* 2001;311:193-7.
109. Apkarian AV, Krauss BR, Fredrickson BE, Szeverenyi NM. Imaging the pain of low back pain: functional magnetic resonance imaging in combination with monitoring subjective pain perception allows the study of clinical pain states. *Neurosci Lett* 2001;299:57-60.
110. Davis KD, Taylor KS, Hutchison WD, et al. Human anterior cingulate cortex neurons encode cognitive and emotional demands. *J Neurosci* 2005;25:8402-6.
111. Apkarian AV, Grachev ID, Krauss BR, Szeverenyi NM. Imaging brain pathophysiology of chronic CRPS pain. In: Harden RN, Baron R, Janig W, eds. *Complex Regional Pain Syndrome*. Seattle: IASP Press; 2001:209-27.
112. Carroll R, Khan A, Zinke J, et al. Increasing levels of anxiety may have reactive temperature effects on post amputation residual limbs. Poster presented at: The Midwest Pain Society Annual Meeting Chicago, IL; September 9-10, 2005.
113. Harden R, Khan A, Zinke J, DiMaio A, Gagnon C. (845): Distal residual limbs in amputees show significant cold perception hypoesthesia. *The Journal of Pain* 2006;7:S62-S.
114. Uematsu S. Thermographic imaging of cutaneous sensory segment in patients with peripheral nerve injury. Skin-temperature stability between sides of the body. *J Neurosurg* 1985;62:716-20.
115. Assessment: thermography in neurologic practice. The American Academy of Neurology, Therapeutics and Technology Assessment Subcommittee. *Neurology* 1990;40:523-5.

116. Brelsford KL, Uematsu S. Thermographic presentation of cutaneous sensory and vasomotor activity in the injured peripheral nerve. *J Neurosurg* 1985;62:711-5.
117. Pulst SM, Haller P. Thermographic assessment of impaired sympathetic function in peripheral nerve injuries. *J Neurol* 1981;226:35-42.
118. Rudy TE, Turk DC, Brena SF. Differential utility of medical procedures in the assessment of chronic pain patients. *Pain* 1988;34:53-60.
119. Schwartzman RJ, McLellan TL. Reflex sympathetic dystrophy: A review. *Arch Neurol* 1987;44:555-61.
120. Ranjbaran Z, Harden RN, Houle T T, Kuiken T A. Decrement in cold perception in amputees correlates with pain intensity. Presented at: The Annual Meeting of the American Academy of Physical Medicine and Rehabilitation Philadelphia, PA; October 27-30, 2005. .
121. Vadada K, Harden RN, Gagnon CM, Gallizzi MA, Arnold N. An investigation of sympathetic reactivity to a cold pressure challenge: A comparison of residual limbs to unaffected contralateral limbs. Poster presented at: The Midwest Pain Society Chicago, IL; October 2007.
122. Dougherty PJ. Long-term follow-up of unilateral transfemoral amputees from the Vietnam war. *The Journal of trauma* 2003;54:718-23.
123. Fischer H. United States Military Casualty Statistics: Operation Iraqi Freedom and Operation Enduring Freedom: Congressional Research Service; 2009 March 25,.
124. Dougherty PJ. Traumatic Amputations During Military Service. In: Traumatic Amputation and Prosthetics: Department of Veterans Affairs Employee Education System; 2002.
125. Harden RN, Bruehl S, Galer B, et al. Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive? *Pain* 1999;83:211-9.
126. Harden RN, Bruehl SP, Gass S, Niemiec C, Barbick B. Signs and symptoms of the myofascial pain syndrome: a national survey of pain management providers. *Clin J Pain* 2000;16:64-72.
127. Kerns RD, Turk DC, Rudy TE. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). *Pain* 1985;23:345-56.
128. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford Press; 1979.
129. McCracken LM, Dhingra L. A short version of the Pain Anxiety Symptoms Scale (PASS-20): preliminary development and validity. *Pain Res Manag* 2002;7:45-50.
130. Tait RC, Pollard CA, Margolis RB, Duckro PN, Krause SJ. The Pain Disability Index: psychometric and validity data. *Arch Phys Med Rehabil* 1987;68:438-41.
131. Melzack R. The short-form McGill Pain Questionnaire. *Pain* 1987;30:191-7.
132. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). *Am J Prev Med* 1994;10:77-84.
133. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. *Curr Med Res Opin* 2006;22:1911-20.
134. Medoc LTD. Medoc manual: TSA-2001 Neuro Sensory Analyzer Model TSA II user and service guide. In. Minneapolis, MN; 2002.
135. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. *Nature* 2001;412:150-7.

136. Ugurbil K, Hu X, Chen W, Zhu XH, Kim SG, Georgopoulos A. Functional mapping in the human brain using high magnetic fields. *Philos Trans R Soc Lond B Biol Sci* 1999;354:1195-213.

Appendix:

**CES-D 10**

Below is a list of the ways you might have felt or behaved. Please tell me how often you have felt this way during the past week.

0= Rarely or none of the time (less than 1 day)  
 1= Some or a little of the time (1-2 days)  
 2= Occasionally or a moderate amount of time (3-4 days)  
 3= Most or all of the time (5-7 days)

1. I was bothered by things that usually don't bother me.	0	1	2	3
2. I had trouble keeping my mind on what I was doing.	0	1	2	3
3. I felt depressed.	0	1	2	3
4. I felt that everything I did was an effort.	0	1	2	3
5. I felt hopeful about the future.	0	1	2	3
6. I felt fearful.	0	1	2	3
7. My sleep was restless.	0	1	2	3
8. I was happy.	0	1	2	3
9. I felt lonely.	0	1	2	3
10. I could not get "going."	0	1	2	3

### PASS

Individuals who experience pain develop different ways to respond to that pain. We would like to know what you do and what you think about when in pain. Please use the rating scale below to indicate how often you engage in each of the following thoughts or activities. Circle any number from 0 (NEVER) to 5 (ALWAYS) for each item.

NEVER

ALWAYS

1.	I think that if my pain gets too severe, it will never decrease .....	0	1	2	3	4	5
2.	When I feel pain I am afraid that something terrible will happen.....	0	1	2	3	4	5
3.	I go immediately to bed when I feel severe pain .....	0	1	2	3	4	5
4.	I begin trembling when engaged in activity that increases pain.....	0	1	2	3	4	5
5.	I can't think straight when I am in pain	0	1	2	3	4	5
6.	I will stop any activity as soon as I sense pain coming on .....	0	1	2	3	4	5
7.	Pain seems to cause my heart to pound or race.....	0	1	2	3	4	5
8.	As soon as pain comes on I take medication to reduce it.....	0	1	2	3	4	5
9.	When I feel pain I think that I may be seriously ill.....	0	1	2	3	4	5
10.	During painful episodes it is difficult for me to think of anything else besides the pain .....	0	1	2	3	4	5
11.	I avoid important activities when I hurt .....	0	1	2	3	4	5
12.	When I sense pain I feel dizzy or faint .....	0	1	2	3	4	5
13.	Pain sensations are terrifying	0	1	2	3	4	5
14.	When I hurt I think about the pain constantly.....	0	1	2	3	4	5
15.	Pain makes me nauseous (feel sick) .....	0	1	2	3	4	5
16.	When pain comes on strong I think I might become paralyzed or more disabled .....	0	1	2	3	4	5
17.	I find it hard to concentrate when I hurt .....	0	1	2	3	4	5
18.	I find it difficult to calm my body down after periods of pain.....	0	1	2	3	4	5
19.	I worry when I am in pain.....	0	1	2	3	4	5
20.	I try to avoid activities that cause pain	0	1	2	3	4	5



## Pain Disability Index

In order to determine how effective your treatment is, we need to know how much pain is interfering in your normal activities. For the 7 areas listed below, please circle the number on the scale which describes the level of disability you have experienced in each area OVER THE PAST WEEK. A score of "0" means no disability at all, and a score of "10" indicates that all of the activities which you would normally do have been totally disrupted or prevented by your pain over the past week. Circle "0" if a category does not apply.

**(1) Family/Home Responsibilities:** This category refers to activities related to the home or family. It includes chores or duties performed around the house (e.g., yard work, house cleaning) and errands or favors for other family members (e.g., driving the children to school).

0	1	2	3	4	5	6	7	8	9	10
No Disability		Mild			Moderate			Severe		Total Disability

**(2) Recreation:** This category includes hobbies, sports, and other similar leisure time activities.

0	1	2	3	4	5	6	7	8	9	10
No Disability		Mild			Moderate			Severe		Total Disability

**(3) Social Activity:** This category refers to activities which involve participation with friends and acquaintances other than family members. It includes parties, theater, concerts, dining out, and other social functions.

0	1	2	3	4	5	6	7	8	9	10
No Disability		Mild			Moderate			Severe		Total Disability

**(4) Occupation:** This category refers to activities that are a part of or directly related to one's job. This includes non-paying jobs as well, such as housewife or volunteer worker.

0	1	2	3	4	5	6	7	8	9	10
No Disability		Mild			Moderate			Severe		Total Disability

**(5) Sexual Behavior:** This category refers to the frequency and quality of one's sex life.

0	1	2	3	4	5	6	7	8	9	10
No Disability		Mild			Moderate			Severe		Total Disability

**(6) Self-Care:** This category includes activities which involve personal maintenance and independent daily living (e.g., taking a shower, driving, getting dressed).

0	1	2	3	4	5	6	7	8	9	10
No Disability		Mild			Moderate			Severe		Total Disability

**(7) Life-Support Activity:** This category refers to basic life-supporting behaviors such as eating and sleeping.

0	1	2	3	4	5	6	7	8	9	10
No Disability		Mild			Moderate			Severe		Total Disability

### Short-Form McGill Pain Questionnaire-2 (Modified) (SF-MPQ-2)

This questionnaire provides you with a list of words that describe some of the different qualities of pain and related symptoms. Please put an X through the numbers that best describe the intensity of each of the pain and related symptoms you felt during the past week. Use 0 if the word does not describe your pain or related symptoms.

1. Throbbing pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
2. Shooting pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
3. Stabbing pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
4. Sharp pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
5. Cramping pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
6. Gnawing pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
7. Hot-burning pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
8. Aching pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
9. Heavy pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
10. Tender	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
11. Splitting pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
12. Tiring-exhausting	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
13. Sickening	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
14. Fearful	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
15. Punishing-cruel	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
16. Electric-shock pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
17. Cold-freezing pain	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
18. Piercing	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
19. Pain caused by light touch	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
20. Itching	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
21. Tingling or 'pins and needles'	none	0	1	2	3	4	5	6	7	8	9	10	worst possible
22. Numbness	none	0	1	2	3	4	5	6	7	8	9	10	worst possible

**Fill in the bubble for the word below which best describes the intensity of your pain NOW:**

- 0 ☐ **NO PAIN**
- 1 ☐ **MILD**
- 2 ☐ **DISCOMFORTING**
- 3 ☐ **DISTRESSING**
- 4 ☐ **HORRIBLE**
- 5 ☐ **EXCRUCIATING**

**Put a mark through the line below to indicate the intensity of your pain NOW:**

No Pain |-----| Worst

Possible Pain mm: \_\_\_\_\_

## FINAL REPORT

1. Award No.: **W23RYX1133N601**
2. Report Date: **December 24, 2014**
3. Reporting period from **September 26, 2011** to **October 25, 2014**
4. PI: **R. Norman Harden, MD**
5. Telephone No.: **(312) 238-7878**
6. Institution: **The Rehabilitation Institute of Chicago**
7. Project Title: **Pathophysiology of Post Amputation Pain**
8. Total staff, with percent effort of each on project.

Norman Harden, MD	33%
Bruni Hirsch	7%
Amy Kirsling	47%
Max Kuroda, PhD	3%

9. Award expenditures to date (as applicable):

Cumulative	Cumulative
Personnel	Travel
Fringe Benefits	Equipment
Supplies	Other
Cumulative	
Subtotal	
Indirect Costs	
Fee	N/A
Total	

10. Comments on administrative and logistical matters.